ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > FDA’s Decision to Approve New Treatment for Alzheimer’s Dise

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Jun 07, 2021 11:56am

116 Views

Post# 33340341

RE:RE:RE:RE:FDA’s Decision to Approve New Treatment for Alzheimer’s Dise

Hopefully BAN2401 will be ready by then and PMN310 next on deck! This is a great day for the fight against AD. I think aducanumab will suprise a little to the upside once they optimize administration timing based on biomarker data.

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo